Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 436.

https://doi.org/10.1182/blood-2023-179818

Published: 2023

Journal Articles

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2023-189369

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Blood (2023) 142 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2023-180743

Published: 2023

Journal Articles

Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)

Seok Jin Kim, Sang Eun Yoon, Deok-Hwan Yang, Sung Yong Oh, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Sung-Nam Lim, Junhun Cho, Won Seog Kim

Blood (2023) 142 (Supplement 1): 301.

https://doi.org/10.1182/blood-2023-174476

Published: 2023

Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Blood (2023) 142 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2023-190995

Published: 2023

Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Blood (2022) 140 (Supplement 1): 1070–1071.

https://doi.org/10.1182/blood-2022-158406

Published: 2022

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Ji Hyun Lee, MD PhD, Sung Yong Oh, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho Sup Lee, MD

Blood (2017) 130 (Supplement 1): 4142.

https://doi.org/10.1182/blood.V130.Suppl_1.4142.4142

Published: 2017

Journal Articles

Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy

Ji Hyun Lee, MD PhD, Sung Yong Oh, Ho Sup Lee, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Won-Sik Lee, MD, Kwon Kyung A, Yoojin Lee, MD, Ho-Jin Shin, MD

Blood (2017) 130 (Supplement 1): 2856.

https://doi.org/10.1182/blood.V130.Suppl_1.2856.2856

Published: 2017

Journal Articles

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

Blood (2017) 130 (Supplement 1): 2840.

https://doi.org/10.1182/blood.V130.Suppl_1.2840.2840

Published: 2017

Journal Articles

the Effect of Erythropoiesis-Stimulating Agent on the Management of Chemotherapy-Induced Anemia and Tumor Growth in Diffuse Large B-Cell Lymphoma Patients

Lee Chun Park, MD, Ho Sup Lee, MD, Da Jung Kim, MD, Jee-yeong Jeong, PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD, Sung Yong Oh, Young Rok Do, MD PhD

Blood (2017) 130 (Supplement 1): 5209.

https://doi.org/10.1182/blood.V130.Suppl_1.5209.5209

Published: 2017

Journal Articles

Treatment of Bilateral Synchronous Ocular Adnexa Marginal Zone Lymphoma: Consortium for Improving Survival of Lymphoma (CISL) Study

Sung Yong Oh, Jin Seok Kim, MD PhD, Ji Hyun Lee, MD PhD, Won Seog Kim, MD, Ph. D., Seok Jin Kim, MD PhD, Dok Hyun Yoon, MD PhD, Jung Yong Hong, Won-Sik Lee, MD, Hyo Jung Kim, MD PhD, Jong-Ho Won, MD, Byeong Park, MD, Soon Il Lee, Cheolwon Suh, MD PhD

Blood (2017) 130 (Supplement 1): 5155.

https://doi.org/10.1182/blood.V130.Suppl_1.5155.5155

Published: 2017

Journal Articles

Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised Stage I or II CD20+ Diffuse Large B-Cell Lymphoma (CISL 12-09)

Dok Hyun Yoon, Byeong Seok Sohn, PhD, Jung Yong Hong, Sung Yong Oh, MD, Won-Sik Lee, Sang Min Lee, Deok-Hwan Yang, Jooryung Huh, Cheolwon Suh

Blood (2016) 128 (22): 4193.

https://doi.org/10.1182/blood.V128.22.4193.4193

Published: 2016

Journal Articles

Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET

Hyewon Lee, MD, Yu Ri Kim, Soo-Jeong Kim, MD, Yong Park, MD PhD, Hyeon-Seok Eom, Sung Yong Oh, MD, Hyo Jung Kim, Hye Jin Kang, Won-Sik Lee, Joon Ho Moon, MD, PhD, Young-Woong Won, MD PhD, Myung Hee Chang, Hye In Park, Jin Seok Kim, MD PhD

Blood (2016) 128 (22): 4205.

https://doi.org/10.1182/blood.V128.22.4205.4205

Published: 2016

Journal Articles

Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

Cheolsu Kim, MD, Ho Sup Lee, MD PhD, Jae-Cheol Jo, MD PhD, Ho-Jin Shin, MD PhD, Sung Yong Oh, MD, Won Sik Lee, MD, Jee-yeong Jeong, PhD

Blood (2016) 128 (22): 4220.

https://doi.org/10.1182/blood.V128.22.4220.4220

Published: 2016

Journal Articles

R-CVP Chemoimmunotherapy for Limited-Stage Ocular Adnexal MALT Lymphoma with Adverse Factors: A Phase II Study

Sung-Yong Kim, MD, Seok-Goo Cho, Won-Sik Lee, MD, Suk-Woo Yang, MD, Sung Yong Oh, MD, Hee Bae Ahn, MD, Deok-Hwan Yang, Seong Kyu Park, Jee Ho Chang, MD, Hyo Jung Kim, MD PhD, Min Joung Lee, Jae Wook Yang

Blood (2016) 128 (22): 2981.

https://doi.org/10.1182/blood.V128.22.2981.2981

Published: 2016

Journal Articles

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

Blood (2016) 128 (22): 1811.

https://doi.org/10.1182/blood.V128.22.1811.1811

Published: 2016

NARROW

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

The Prognostic Implication of Inflammatory Factor-Based Scoring System in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era

Pretreatment Nutritional Status and Cardiovascular Risk Factors Affect Survival of Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

the Effect of Erythropoiesis-Stimulating Agent on the Management of Chemotherapy-Induced Anemia and Tumor Growth in Diffuse Large B-Cell Lymphoma Patients

Treatment of Bilateral Synchronous Ocular Adnexa Marginal Zone Lymphoma: Consortium for Improving Survival of Lymphoma (CISL) Study

Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised Stage I or II CD20+ Diffuse Large B-Cell Lymphoma (CISL 12-09)

Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET

Clinical Usefulness of Inflammatory Factors Based Modified International Prognostic Index in Diffuse Large B Cell Lymphoma Treated with Rituximab Combined Chemotherapy

R-CVP Chemoimmunotherapy for Limited-Stage Ocular Adnexal MALT Lymphoma with Adverse Factors: A Phase II Study

Phase II Trial of R-CVP Followed By Rituximab Maintenance Therapy for Patients with Advanced Stage Marginal Zone Lymphoma- Consortium for Improving Survival of Lymphoma (CISL) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only